(NU/1433-27) iFAST: The Provision of Business Consultancy to Assist Commercialisation of University Research.
What the buyer wrote
The emergence of bacteria that are resistant to antibiotics is a growing public health problem. In 2015, there were nearly 700,0000 antimicrobial resistance (AMR) infections in the EU, accounting for 33,000 deaths and 900,000 disability-adjusted life years (DALYs) . In fact the impact of AMR is similar to the combined burden of influenza, tuberculosis, and HIV, and the global increases in healthcare costs is forecast to range from $300 billion to more than $1 trillion per year by 2050. We have developed a breakthrough technology that delivers an antibiotic resistance test result in 1 hour. The technique rapidly measures phenotypic changes in bacteria after exposure to antibiotics. The object…
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Details
- What the buyer calls it
- (NU/1433-27) iFAST: The Provision of Business Consultancy to Assist Commercialisation of University Research.
- How they are buying
- Advertised, shortlist firstSuppliers applied to be considered, and the buyer picked who went on to bid.
- Type
- services
- Dynamic market
- Yes: you can apply to join at any time. How these work
- Kind of work
- Professional services
Who the buyer named
Emma Barksby was the named contact on this notice.